Company Name, Ticker, Customers, else..

Anixa Biosciences Inc (NASDAQ: ANIX)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Anixa Biosciences Inc 's

Name: Anixa Biosciences Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ANIX Sales vs. its Competitors Q3 2026

Comparing the current results to its competitors, Anixa Biosciences Inc reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.45 %, recorded in the same quarter.

• List of ANIX Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Anixa Biosciences Inc recorded a net loss, as well as most of its competitors.

<< ANIX Stock Performance Comparisons

Anixa Biosciences Inc 's Comment on Competition and Industry Peers

The company operates in the biopharmaceutical industry, which is characterized by intense competition in developing new technologies and proprietary therapies. Competitors include larger pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research organizations. Many of these competitors possess greater financial, technical, and human resources, as well as more experience in product development, regulatory approvals, and commercialization. Their therapies and vaccines may be more effective or better marketed, which could impact the competitiveness of the company's products. Additionally, industry mergers and acquisitions may lead to increased resource concentration among fewer competitors.

<< See the full list of ANIX competitors

*Market share is calculated based on total revenue.

ANIX's Stock Performance relative to its Competitors

Publicly Traded Peers of Anixa Biosciences Inc

Zymeworks Inc
Share Performance

+67.09%

One Year

Zymeworks Inc

Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1,919.724 mill.	$ 37.127 mill.	$ -149.992 mill.

Oramed Pharmaceuticals Inc
Share Performance

+28.83%

This Quarter

Oramed Pharmaceuticals Inc

Profile

Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.

More about Oramed Pharmaceuticals Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 199.858 mill.	$ - mill.	$ 174.864 mill.

Ocean Biomedical Inc
Share Performance

+700.00%

This Quarter

Ocean Biomedical Inc

Profile

Ocean Biomedical develops biopharmaceutical products licensed from research institutions.

More about Ocean Biomedical Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.073 mill.	$ - mill.	$ -28.983 mill.

Nextcure Inc
Share Performance

+221.46%

This Quarter

Nextcure Inc

Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 39.770 mill.	$ - mill.	$ -42.748 mill.

Nuvalent Inc
Share Performance

+0.05%

Over The Past 5 Days

Nuvalent Inc

Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,751.979 mill.	$ - mill.	$ -450.074 mill.

39 more competitors available

Sources: Anixa Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Saturday, September 12, 2026 6:57 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Anixa Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.